Literature DB >> 17101120

Evidence that the deficit in sexual behavior in adult rats neonatally exposed to citalopram is a consequence of 5-HT1 receptor stimulation during development.

Dorota Maciag1, David Coppinger, Ian A Paul.   

Abstract

Neonatal (postnatal days 8-21) exposure of rats to the selective serotonin reuptake inhibitor (SSRI), citalopram, results in persistent changes in behavior including decreased sexual activity in adult animals. We hypothesized that this effect was a consequence of abnormal stimulation of 5-HT(1A) and/or 5-HT(1B) receptors as a result of increased synaptic availability of serotonin during a critical period of development. We examined whether neonatal exposure to a 5-HT(1A) (8OH-DPAT) or a 5-HT(1B) (CGS 12066B) receptor agonist can mimic the effect of neonatal exposure to citalopram on adult sexual behavior. Results showed that neonatal treatment with 5-HT(1B) receptor agonist robustly impaired sexual behavior similar to the effect of citalopram, whereas exposure to 5-HT(1A) receptor agonist only moderately influenced male sexual activity in adult animals. These data support the hypothesis that stimulation of serotonin autoreceptors during development contributes to the adult sexual deficit in rats neonatally exposed to citalopram.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101120      PMCID: PMC1762094          DOI: 10.1016/j.brainres.2006.10.009

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  33 in total

1.  Placental passage of antidepressant medications.

Authors:  Victoria Hendrick; Zachary N Stowe; Lori L Altshuler; Sun Hwang; Emily Lee; Desiree Haynes
Journal:  Am J Psychiatry       Date:  2003-05       Impact factor: 18.112

2.  Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study.

Authors:  Irena Nulman; Joanne Rovet; Donna E Stewart; Jacob Wolpin; Pia Pace-Asciak; Samar Shuhaiber; Gideon Koren
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

3.  Perinatal outcome following third trimester exposure to paroxetine.

Authors:  Adriana Moldovan Costei; Eran Kozer; Tommy Ho; Shinya Ito; Gideon Koren
Journal:  Arch Pediatr Adolesc Med       Date:  2002-11

Review 4.  Molecular, pharmacological and functional diversity of 5-HT receptors.

Authors:  Daniel Hoyer; Jason P Hannon; Graeme R Martin
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

5.  The role of the 5-HT2 receptor in the regulation of sexual performance of male rats.

Authors:  M M Foreman; J L Hall; R L Love
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

6.  Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy.

Authors:  Regina C Casper; Barry E Fleisher; Julie C Lee-Ancajas; Allyson Gilles; Erika Gaylor; Anne DeBattista; H Eugene Hoyme
Journal:  J Pediatr       Date:  2003-04       Impact factor: 4.406

7.  Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.

Authors:  Kari Laine; Tuija Heikkinen; Ulla Ekblad; Pentti Kero
Journal:  Arch Gen Psychiatry       Date:  2003-07

8.  Impairments of ERK signal transduction in the brain in a rat model of depression induced by neonatal exposure of clomipramine.

Authors:  Pingfu Feng; Zhiwei Guan; Xiaoping Yang; Jidong Fang
Journal:  Brain Res       Date:  2003-11-21       Impact factor: 3.252

9.  Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior.

Authors:  Philip Sanford Zeskind; Laura E Stephens
Journal:  Pediatrics       Date:  2004-02       Impact factor: 7.124

Review 10.  Diagnosis and treatment of depression during pregnancy.

Authors:  Lee S Cohen; Ruta Nonacs; Adele C Viguera; Alison Reminick
Journal:  CNS Spectr       Date:  2004-03       Impact factor: 3.790

View more
  12 in total

Review 1.  Maternal SSRIs experience and risk of ASD in offspring: a review.

Authors:  Zainab Fatima; Aqeela Zahra; Maria Ghouse; Xu Wang; Zonghui Yuan
Journal:  Toxicol Res (Camb)       Date:  2018-07-11       Impact factor: 3.524

2.  Dose-dependent effects of neonatal SSRI exposure on adult behavior in the rat.

Authors:  Sharonda S Harris; Dorota Maciag; Kimberly L Simpson; Rick C S Lin; Ian A Paul
Journal:  Brain Res       Date:  2011-10-20       Impact factor: 3.252

3.  Mood disorders and their pharmacological treatment during pregnancy: is the future child affected?

Authors:  Catherine Monk; Elizabeth M Fitelson; Elizabeth Werner
Journal:  Pediatr Res       Date:  2011-05       Impact factor: 3.756

4.  Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring.

Authors:  Jocelien D A Olivier; A Vallès; Floor van Heesch; Anthonieke Afrasiab-Middelman; Janneke J P M Roelofs; Marloes Jonkers; Elke Joan Peeters; Gerdien A H Korte-Bouws; Jos P Dederen; Amanda J Kiliaan; Gerard J Martens; Dirk Schubert; Judith R Homberg
Journal:  Psychopharmacology (Berl)       Date:  2011-04-14       Impact factor: 4.530

Review 5.  Of rodents and humans: A comparative review of the neurobehavioral effects of early life SSRI exposure in preclinical and clinical research.

Authors:  Matthew E Glover; Sarah M Clinton
Journal:  Int J Dev Neurosci       Date:  2016-05-07       Impact factor: 2.457

6.  Developmental fluoxetine exposure facilitates sexual behavior in female offspring.

Authors:  Ine Rayen; Harry W M Steinbusch; Thierry D Charlier; Jodi L Pawluski
Journal:  Psychopharmacology (Berl)       Date:  2013-07-31       Impact factor: 4.530

Review 7.  Psychoactive drug exposure during breastfeeding: a critical need for preclinical behavioral testing.

Authors:  Irving Zucker
Journal:  Psychopharmacology (Berl)       Date:  2018-03-16       Impact factor: 4.530

8.  Cognitive impairments from developmental exposure to serotonergic drugs: citalopram and MDMA.

Authors:  Tori L Schaefer; Curtis E Grace; Amanda A Braun; Robyn M Amos-Kroohs; Devon L Graham; Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-11       Impact factor: 5.176

9.  Neonatal citalopram treatment inhibits the 5-HT depleting effects of MDMA exposure in rats.

Authors:  Tori L Schaefer; Curtis E Grace; Matthew R Skelton; Devon L Graham; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  ACS Chem Neurosci       Date:  2011-10-21       Impact factor: 4.418

10.  Histological changes in the liver of fetuses of pregnant rats following citalopram administration.

Authors:  Zeynab Mohammadi; Mahnaz Azarnia; Ghadireh Mirabolghasemi; Abdolhossein Shiravi; Zohreh Mohammadi
Journal:  Indian J Pharmacol       Date:  2013 Sep-Oct       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.